L-Taurine, L-Glycine, L-Arginine, Daidzein, Proanthocyanidin, Vitamin B1 and Vitamin B6 show positive effects on decreasing fibromyalgia induced symptoms. A Randomized, Double-Blind, Placebo-Controlled Study

Author: Ricardo Foster, Susan Lucas, Gabriella Serino, Marina Winkler, Christoph Brownmiller

Abstract

This study aimed to investigate the effects of L-Taurine, L-Glycine, L-Arginine, Daidzein, Proanthocyanidin, Vitamin B1 and Vitamin B6 on decreasing fibromyalgia induced symptoms. We conducted a randomized, double-blind, placebo-controlled study on 142 patients aged 32-81 years old diagnosed with fibromyalgia. The participants were randomized to receive tablets containing L-Taurine (10 mg/day), L-Glycine (10 mg/day), L-Arginine (7 mg/day), Proanthocyanidin (5 mg/day), Daidzein (3 mg/day), Vitamin B6 (1 mg/day) and Vitamin B1 (0,5mg/day) or a placebo for 16 weeks. After 16 weeks, 94% (n=67) of participiants reported a significant reduction of fibromyalgia induced symptoms. However in the placebo group only 10% (n=7) of participants reported a significant reduction of fibromyalgia induced symptoms.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Bhargava J, Hurley JA. Treasure Island, FL: StatPearls Publishing;
2. Branch NSC and O: Fibromyalgia. Fibromyalgia. [ Jun; 2023 ]. 2023.
3. Treatment of fibromyalgia. Kwiatek R. Aust Prescr. 2017;40:179–183.
4. EULAR revised recommendations for the management of fibromyalgia. Macfarlane GJ, Kronisch C, Dean LE, et al. Ann Rheum Dis. 2017;76:318–328.
5. Pharmacological management of fibromyalgia: a Bayesian network meta-analysis. Migliorini F, Maffulli N, Eschweiler J, Knobe M, Tingart M, Colarossi G. Expert Rev Clin Pharmacol. 2022;15:205–214.
6. Progress towards improved non-pharmacological management of fibromyalgia. Pinto AM, Geenen R, Castilho P, da Silva JA. Joint Bone Spine. 2020;87:377–379.
7. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Sim J, Adams N. Clin J Pain. 2002;18:324–336.
8. Effects of lifestyle physical activity in adults with fibromyalgia: results at follow-up. Fontaine KR, Conn L, Clauw DJ. J Clin Rheumatol. 2011;17:64–68.
9. Lifestyle-oriented non-pharmacological treatments for fibromyalgia: a clinical overview and applications with home-based technologies. Friedberg F, Williams DA, Collinge W. J Pain Res. 2012;5:425–435.
10. International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgia. Kundakci B, Hall M, Atzeni F, et al. Semin Arthritis Rheum. 2022;57:152101.
11. Evidence-based non-pharmacological therapies for fibromyalgia. Aman MM, Jason Yong R, Kaye AD, Urman RD. Curr Pain Headache Rep. 2018;22:33.
12. Patients’ perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia. Taylor SJ, Steer M, Ashe SC, Furness PJ, Haywood-Small S, Lawson K. Scand J Pain. 2019;19:167–181.
13. Management of fibromyalgia syndrome in 2016. Okifuji A, Gao J, Bokat C, Hare BD. Pain Manag. 2016;6:383–400.
14. Pharmacological treatment options for fibromyalgia. Northcott MJ, Guymer EK, Littlejohn GO. Clin Pharm. 2017;9
15. Fibromyalgia: presentation and management with a focus on pharmacological treatment. Sumpton JE, Moulin DE. Pain Res Manag. 2008;13:477–483.
16. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. Arnold LM, Russell IJ, Diri EW, et al. J Pain. 2008;9:792–805.
17. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Clin Ther. 2008;30:1988–2004.
18. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. J Rheumatol. 2009;36:398–409.
19. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. Pain. 2005;119:5–15.
20. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. J Rheumatol. 2010;37:2578–2586.
21. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K. Arthritis Res Ther. 2015;17:224.
22. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, Chappell AS. Prim Care Companion J Clin Psychiatry. 2009;11:237–244

Skills

Posted on

June 27, 2022